Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in New Haven, CT
NPI: 1043409691Primary Practice Location
YALE-NEW HAVEN HOSPITAL
35 Park St, New Haven, CT
Primary Employer
Yale Medicine
yalemedicine.org
HQ Phone
Get M.D. Michael's Phone Numberphone_androidMobile
Get M.D. Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCT State Medical License
Icahn School Of Medicine At Mount Sinai
icahn.mssm.edu
Medical School
Until 2000
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 200 | 516 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 92 | 211 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 22 | 40 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 22 | 22 |
| 5 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 19 | 19 |
Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
Authors: LeClair, Jessica N, Merl, Man Yee, Cohenuram, Michael, Luon, Darren
Journal: Clin Lung Cancer
Publication Date: 2021-08-16
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, PROCEDURE: Positron Emission Tomography, BIOLOGICAL: Bevacizumab, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Atezolizumab, DRUG: Fluorouracil, PROCEDURE: Computed Tomography, DRUG: Oxaliplatin, DRUG: Leucovorin
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Pembrolizumab, OTHER: Pharmacological Study, PROCEDURE: Biospecimen Collection, OTHER: Clinical Observation, OTHER: Quality-of-Life Assessment, PROCEDURE: Computed Tomography, PROCEDURE: Cystoscopy, PROCEDURE: CT Urography
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), Division of Cancer Control, NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP), Canadian Cancer Trials Group
Intervention / Treatment: OTHER: Weight Loss Intervention, OTHER: Health Education Program
